The ability of bio-pharmaceutical manufacturers to deliver quality drug products during challenging market conditions is critical for ensuring sustainability over the long run. The COVID-19 pandemic underscored the need to transform the traditional bio-pharmaceutical supply chain to have greater agility and resiliency during market swings and periods of volatility.
Please join Pharmaceutical Outsourcing Editor-in-Chief Mike Auerbach for a lively discussion with industry experts Daniel Matlis, President and Founder, Axendia, and David Leitham, SVP and GM, Pharmaceutical Business Unit, AspenTech, as they address these hot-button topics:
Who should attend: